{
    "eid": "2-s2.0-85010297635",
    "title": "Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia",
    "cover-date": "2017-03-01",
    "subject-areas": [
        {
            "$": "Hematology",
            "@code": "2720"
        }
    ],
    "keywords": [
        "chelation",
        "deferasirox",
        "liver iron concentration",
        "serum ferritin",
        "thalassaemia"
    ],
    "authors": [
        "John B. Porter"
    ],
    "citedby-count": 31,
    "ref-count": 42,
    "ref-list": [
        "Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality",
        "Pathogenesis and management of iron toxicity in thalassemia",
        "Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine",
        "Serum ferritin levels and endocrinopathy in medically treated patients with \u03b2 thalassemia major",
        "Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major",
        "Non-invasive assessment of tissue iron overload.",
        "Iron-chelating therapy and the treatment of thalassemia",
        "Guidelines for the Clinical Management of Thalassaemia",
        "Body iron metabolism and pathophysiology of iron overload",
        "Iron-chelation therapy with oral deferiprone in patients with thalassemia major",
        "Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with \u03b2-thalassemia",
        "Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study",
        "Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload",
        "Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload",
        "Iran J Ped Hematol Oncol",
        "Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion-dependent thalassemia",
        "Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias",
        "Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders",
        "Guidelines for the management of transfusion dependent thalassaemia (TDT)",
        "Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients",
        "Correlation between serum ferritin levels and liver iron concentration determined by MR imaging: impact of hematologic disease and inflammation",
        "Liver iron concentrations and urinary hepcidin in \u03b2-thalassemia",
        "Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia",
        "Blood",
        "Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with \u03b2-thalassaemia major: Application of SQUID biomagnetic liver susceptometry",
        "Binding of Serum Ferritin to Concanavalin A: Patients with Hornozygous \u03b2 Thalassaemia and Transfusional Iron Overload",
        "Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan",
        "Hepatic iron concentration and total body iron stores in thalassemia major",
        "Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration",
        "Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases",
        "Treatment of cardiac iron overload in thalassemia major",
        "Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias",
        "Efficacy and safety of deferasirox at low and high iron burdens: Results from the EPIC magnetic resonance imaging substudy",
        "Single spin-echo proton transverse relaxometry of iron-loaded liver",
        "Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance",
        "Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation",
        "ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture",
        "Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies",
        "Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells",
        null,
        "Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major",
        "Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with \u03b2-thalassemia major and severe iron burden"
    ],
    "affiliation": [
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Cairo",
            "affilname": "Ain Shams University Children's Hospital",
            "affiliation-country": "Egypt"
        },
        {
            "affiliation-city": "Cairo",
            "affilname": "Cairo University Hospitals",
            "affiliation-country": "Egypt"
        },
        {
            "affiliation-city": "London",
            "affilname": "UCL Cancer Institute",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Beirut",
            "affilname": "American University of Beirut",
            "affiliation-country": "Lebanon"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Izmir",
            "affilname": "Ege University Medical School",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "St George Hospital",
            "affiliation-country": "Australia"
        }
    ],
    "funding": [
        "Novartis",
        "Novartis Pharmaceuticals Corporation",
        "Seventh Framework Programme",
        "Seventh Framework Programme",
        "NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research",
        "University College London"
    ]
}